COVID Patient Support Program Extension: Free Medication from Bristol Myer Squibb (BMS) Below is the letter we received with the details for this remarkable COVID inspired program. It contains links to a... January 27, 2021Business, Finances, Insurance & Regulatory, C19 - Updates, NewsBy Brad Hedrick
NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL... January 4, 2021Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients... November 25, 2020Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia Calquence (acalabrutinib) is a 2nd generation BTK inhibitor with a different side effect profile than ibrutinib. It is already approved... November 13, 2020Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
NICE okays chemotherapy-free combination venetoclax plus obinutuzumab for all front-line patients with chronic lymphocytic leukaemia (CLL) NICE gives green light for chemotherapy-free combination of venetoclax plus obinutuzumab for all front-line patients with CLL ... November 13, 2020Business, Finances, Insurance & Regulatory, NewsBy Brad Hedrick
The LLS CLL Co-Pay Assistance Fund is Open! LLS may be able to help pay your insurance premiums and co-pays if you are in active treatment or are... October 30, 2020Business, Finances, Insurance & RegulatoryBy Brad Hedrick
FDA Grants Fast Track Designation to Ublituximab Plus Umbralisib in Chronic Lymphocytic Leukemia With this fast track designation, the combination of ublituximab and umbralisib should move through the FDA's approval process more quickly,... October 27, 2020Business, Finances, Insurance & RegulatoryBy Brad Hedrick
New approval for venetoclax for Acute Myeloid Leukemia (AML) The U.S. Food and Drug Administration (FDA) has granted full approval of venetoclax in combination with azacitidine, or decitabine, or... August 20, 2020Business, Finances, Insurance & RegulatoryBy Brad Hedrick
FDA Clearance for clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia (CLL) This is good news for CLL patients as measurement for MRD (minimal or measurable residual disease) is increasingly being recognized... August 11, 2020Business, Finances, Insurance & Regulatory, MRD & Disease MonitoringBy Brad Hedrick
Gilead Gets Another CAR-T Approval, This Time for Mantle Cell Lymphoma Hopefully the next approval will be for CLL patients, but there is still much work to be done in clinical... July 27, 2020Business, Finances, Insurance & Regulatory, CAR-TBy Brad Hedrick
